Publications by authors named "Aynil Dalkıran"
Article Synopsis
- The study examined whether inhaled corticosteroids affect the severity and mortality of COVID-19 pneumonia among patients with chronic asthma and COPD.
- It was a retrospective observational study, comparing two groups: one that used inhaled corticosteroids and one that did not, finding no significant difference in pneumonia severity between the groups.
- Key risk factors for mortality included increasing age, mechanical ventilation, severe pneumonia, interstitial lung disease, and the use of prone position, while inhaled corticosteroid use did not correlate with increased severity or mortality.
Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.
Sarcoidosis Vasc Diffuse Lung Dis
September 2023
Background: We aimed to evaluate the pulmonary involvement status, its related factors, and pulmonary function test (PFT) results in the first month follow-up in patients who were discharged for severe Covid-19 pneumonia, and to assess the efficacy of corticosteroid treatment on these parameters in severe pulmonary involvement patients.
Methods: We retrospectively analyzed all consecutive patients who applied to our COVID-19 follow-up clinic at the end of the first month of hospital discharge. Functional and radiological differences were compared after 3 months of corticosteroid treatment in severe pulmonary involvement group.
Background: The aim of the study is to assess the effect of chronic lung disease on mortality in patients hospitalized with the diagnosis of prevariant COVID-19 Pneumonia compared to patients without chronic lung disease.
Research Design And Methods: A cohort of 1,549 patients admitted to the pandemic clinic with a COVID-19 Pneumonia diagnosis was analyzed. Group 1 and Group 2 were compared in terms of the treatment they received, admission to intensive care, mortality and follow-up parameters.